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Tongueenlargementandmandibularprognathismareclinicallyrecognizedinalmostallpatientswithacromegaly.Anacromegaly-
like rat model recently developed by exogenous administration of insulin-like growth factor I (IGF-I) was used to investigate
morphological and histopathological changes in orofacial structures and to clarify whether these changes were reversible.
Exogenous administration of IGF-I evoked speciﬁc enlargement of the tongue with identiﬁable histopathological changes
(increased muscle bundle width, increased space between muscle bundles, and increased epithelial thickness), elongation of the
mandibular alveolar bone and ascending ramus, and lateral expansion of the mandibular dental arch. Regarding histopathological
changes in the mandibular condyle, the cartilaginous layer width, bone matrix ratio, and number of osteoblasts were all
signiﬁcantly greater in this rat model. After normalization of the circulating IGF-I level, tongue enlargement and histopathological
changes in the tongue and mandibular condyle were reversible, whereas morphological skeletal changes in the mandible remained.
1.Introduction
In acromegalic or acrogiantic patients, growth hormone
(GH) is oversecreted, generally due to a GH-secreting pitu-
itary adenoma (GH-oma). GH stimulates the production of
insulin-like growth factor I (IGF-I), which mediates the
growth-promoting actions of GH. IGF-I overexpression
causes a variety of gradual morphological orofacial changes,
such as tongue enlargement, lip thickening, increased sinus
volume, and mandibular prognathism [1–6]. These changes
are considered the most deﬁnitive signs of acromegaly (acro-
giantism) and are found in almost all cases. Enlargement of
the tongue and mandibular protrusion often cause masti-
catory disturbances, dysphagia, speech diﬃculties, and/or
aesthetic problems, resulting in a marked decrease in the
patient’s quality of life. When devising a treatment plan
for these functional disturbances, it is important to know
whether these enlarged tissues improve after IGF-I serum
levels return to normal. However, there are no detailed
reports regarding the morphological or histopathological
changes in orofacial structures that accompany acromegaly,
probably because of diﬃculty of the evaluation in human
subjects. Consequently, whether such changes are reversible
after normalization of the circulating IGF-I levels in humans
following removal of a GH-oma is unknown.
This paper will focus on the time course of tongue en-
largement and jaw bone growth during IGF-I overexpression
and after IGF-I normalization, based on a series of studies
using an acromegaly-like rat model developed by exogenous
administration of IGF-I [7–10].2 International Journal of Endocrinology
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Figure 1: (a, b) Serum levels of human and rat IGF-I (a), and total IGF-I (b) during and after administration of human IGF-I (∗∗∗P<0.001
versus control). (c) Body weight, as a percentage of initial value in the same animal, during and after administration of human IGF-I
(∗∗P<0.01, ∗∗∗P<0.001 versus control). In (a)–(c), data represent the mean ± SD of six rats, adapted from a previous report [7].
2. AnimalPreparation
Prior approval for all research protocols was obtained
from the Institute for Experimental Animals at Tohoku
University School [7–10], the experimental animals were
male Wistar rats at 10 weeks of age [7–10]. During the 8-
week experimental period, animals were housed individually
in a controlled environment at 23◦C with a 12h light/dark
cycle and with free access to tap water and food. The
rats were divided into two equal groups: an experimental
group treated with human recombinant IGF-I and a sham
controlgroup.HumanrecombinantIGF-I(SOMAZON)was
kindly provided by Astellas Pharma, Inc. (Tokyo, Japan).
For 4 weeks, rats in the IGF-I group were continuously
subcutaneously infused with 640μg/day IGF-I dissolved in
saline using implanted osmotic minipumps (Model 2002,
Alza Corp., Palo Alto, CA, USA). Rats in the control group
were infused with saline alone by the same method. After
the pumps had been removed at 14 weeks of age, rats were
housed (as described) for an additional 4 weeks. All surgical
procedures for the implantation and removal of pumps were
performed under ether anesthesia.
3. Effects of IGF-I Administration
3.1. IGF-I Serum Level and Body Weight. Serum levels of rat
IGF-I and human IGF-I were measured by radioimmunoas-
say [7, 11]. As show in Figure 1(a),h u m a nI G F - Il e v e l si n
the serum increased immediately and remained at a high
level throughout the administration period [7]. In contrast,
the level of endogenous rat IGF-I decreased signiﬁcantly
during the administration period [7], indicating that some
negative feedback mechanism(s) may be involved. Similarly,
Bermann et al. [12] previously reported that recombinant
human IGF-I exerts a powerful negative feedback on GH
secretion in healthy humans, stimulating hypothalamic so-
matostatin secretion in particular. Thus, it seems likely that
the circulating level of endogenous rat IGF-I decreased
due to suppression of the rat’s own GH concentration.International Journal of Endocrinology 3
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Figure 2: (a) Changes in body weight and soft oral tissue weight at 14 weeks of age in the IGF-I group compared to control (∗P<0.05
versus total body weight). (b) Tongue weight at 14 and 18 weeks of age in IGF-I-treated and control rats (∗∗∗P<0.001 versus control). Data
represent the mean ± SD of six rats, adapted from a previous report [8].
In the rat model, the total circulating IGF-I (human + rat)
was approximately 1.7 to 1.9 times higher than in the control
group (Figure 1(b)). Body weight increased during IGF-I
administration (Figure 1(c))[ 7].
3.2. Tongue. In the rat model, enlargement of the tongue was
observed after 4 weeks of IGF-I treatment and was speciﬁc to
the tongue compared to other oral soft tissues (i.e., masseter
muscle, sublingual gland, submandibular gland, and parotid
gland) (Figures 2(a) and 2(b))[ 8]. This is consistent with
clinical reports showing the occurrence of an enlarged
tongue to be substantial (from 84% to 95%) in patients with
acromegaly [1, 2]. We conducted histopathological examina-
tion of specimens stained with hematoxylin-eosin to analyze
factors that lead to tongue enlargement [8] (Figures 3(a)
and 3(b)). No demonstrable change in the subepithelial
connectivetissuecouldbeseeninourratmodel(Figures 3(a)
and 3(b)), although one previous clinical case report did
show increased subepithelial connective tissue [13]. Muscle
bundle width and thickness of the epithelium were both
signiﬁcantly greater in the rat model than in control rats
[8] (Figures 3(c) and 3(e)). This result is supported by a
clinical report showing that acromegalic tongues at autopsy
h a de n l a r g e dl i n g u a lm u s c l eﬁ b e r s( t w i c ea sl a r g ea si n
normal subjects) and a thickened tongue epithelium due to
marked acanthosis [13]. Desnoyers et al. [14] have shown
that the IGF receptor is distributed in myoﬁbrils of the
rat tongue, and Donath et al. [15] demonstrated that IGF-
I stimulates expression of myoﬁbrillar gene. Taking these
observations together, it seems clear that IGF-I stimulated
the proliferation of myoﬁbrils in our rat model. In addition,
the ratio of muscle parts in the rat model was signiﬁcantly
smaller than in the control (Figure 3(d)), indicating that the
spaces between muscle bundles in the rat model increased
[8]. Increased spaces between muscle bundles may indicate,
at least in part, an increase in extracellular ﬂuid component.
Thisalsoagreeswellwithclinicalreportsinhumans[16–20],
which indicate that increases in extracellular ﬂuid volume in
acromegalyarecausedbytheactiveeﬄuxofsodiumfromthe
intracellular pool due to activation of Na+-K+ transport, and
that skeletal muscle potassium content is higher in patients
with acromegaly than in weight-matched healthy controls.
Furthermore, Dorup and clausen [20] demonstrated that
IGF-I stimulates the Na+-K+ pump and increases 42Ku p t a k e
and 22Na eﬄux in isolated rat soleus muscle.
3.3. Jaw Bones. We compared the enlargement of the man-
dible with that of the maxilla and femur in the rat model
to verify clinical ﬁndings showing the enlargement of the
mandible as the most severe skeletal change in acromegalic
patients [2, 3, 7, 21]. The length of the alveolar bones of
the mandible and maxilla were evaluated on a plaster model
obtained from a precise impression of each dental arch
(Figure 4(a)). The lengths of the right femurs were mea-
s u r e do nX - r a yp h o t o g r a p h s( Figure 4(b)). The mandibular
alveolar bone, maxillary alveolar bone, and femur were all
elongated during IGF-I administration (Figure 4(c))[ 7].
Elongation was greatest in the mandible, indicating that the
amount of bone growth diﬀered from site to site. Malpe
et al. [22] have reported that levels of IGFs and IGF-
binding proteins (IGFBP-1 to -6), which have inhibitory4 International Journal of Endocrinology
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Figure 3: (a, b) Coronal sections of the dorsal superior longitudinal tongue muscle from an IGF-I-treated rat (a) and a control rat (b) at 14
weeks of age (hematoxylin-eosin staining, 100x magniﬁcation, bars = 100μm). (c–e) Muscle bundle width (c), ratio of the muscle parts (d),
and total epithelial thickness (e). In (c–e), data represent the mean ± SD of six rats (∗P<0.05, ∗∗P<0.01, ∗∗∗P<0.001 versus control);
adapted from a previous report [8].International Journal of Endocrinology 5
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Figure 4: (a, b)Illustrationshowinglength measurements ofthemandibular alveolar bone(a)andfemur (b).Measurement ofthemaxillary
alveolar bone (not shown) was the same as for the mandible. (c) Bone length during and after administration of human IGF-I, shown as a
percentage of bone length in the control group at the same time (∗P<0.05, mandibular alveolar bone versus other bones). Data represent
the mean ± SD of six rats, adapted from a previous report [7].
or stimulatory modulating eﬀects on the local actions of IGF,
varied signiﬁcantly among skeletal sites (calvaria, mandible,
rib, vertebra, and marrow stroma) in humans. Furthermore,
they reported that human calvarial and mandibular cells
produce especially high levels of IGFBP-5, which stimulates
bone cell proliferation and potentiates the actions of IGFs.
These site-speciﬁc IGFBP levels suggest a possible mecha-
nism for our ﬁnding that the growth rate was higher in
the mandible than in either the maxilla or femur. Over a
century ago, Chalk [23] and Benda [24] concluded that
an enlarged tongue may be related to the etiology of the
mandibular prognathism seen in patients with acromegaly.
Clinical ﬁndings also suggest that an enlarged tongue aﬀects
the size and shape of the jaw [1].
To clearly detail the changes that occur in the dental
arches of patients with acromegaly, we investigated the time
course of changes in the width, length, and angle of the
mandibular and maxillary dental arches in rat models using
the plaster models mentioned above (Figures 5(a)–5(c))
[9]. We found that mandibular arch growth was greater in
the lateral direction than in the anteroposterior direction
(Figures 5(a)–5(c))[ 9]. This result is consistent with a clin-
ical report showing increased lateral growth in the man-
dibles of humans with acromegaly, which is expected to
induce the lateral cross-bite in these patients [25]. Indeed, a
previous study using plaster models of 28 case of acromegaly
demonstrated that the mandible was larger than the maxilla
in 32% of patients, and that the maxilla was captured in
the mandible in one patient [5]. An enlarged tongue should
be one of the explanation of the remarkable lateral dental
arch expansion in the mandible because tongue enlargement
wouldhavethepotentialtowidenthearchbyapplyinglateral
pressure to the teeth.
Kunzler and Farmand [2] observed 31 patients with
persistent symptoms of GH-oma. Using X-ray photographs
of the facial skeleton, they reported that these patients exhib-
ited signiﬁcant bone changes only in the mandible (length
of the ascending ramus, length of the mandibular body,
and chin prominence). In our rat model, the length of the
ascending ramus was speciﬁcally and signiﬁcantly increased,
but there were no signiﬁcant increases in the length of the
coronoid or angular processes (Figures 6(a) and 6(b))[ 10].6 International Journal of Endocrinology
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Figure 5: Left: illustration showing measurements for width (a), length (b), and angle θ (c) of the mandibular dental arch. Measurements
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Figure 6: (a) Lateral cephalometric image showing the basal points
formandibular morphological analysis.MaF:mostinferior pointof
the mandibular foramen; MeF: mental foramen; Cd: most posterior
point of the condyle; Cr: tip of the coronoid process; Go: tip of
the angular process. (b) Mandibular morphological change as a
percentage of MeF-MaF in the same animal. Data represent the
mean ± SD of six rats (∗P<0.05, ∗∗P<0.01 versus control),
adapted from a previous report [10].
These ﬁndings are supported by published evidence that
IGF-I stimulates chondrocyte activity in the growth plate
a n dp r o m o t e sb o n ee l o n g a t i o n[ 26–28], and that normal
growth in the ascending ramus is due to endochondral
ossiﬁcation of the mandibular condyle [29–31]. In the rat
model, histopathological changes in the mandibular condyle
show a marked increase in width of the cartilaginous layer
(Figures 7(a)–7(c))[ 10]. Regarding the eﬀect of IGF-I on the
articular cartilage of the mandibular condyle, Blumenfeld et
al. [32] reported that in vitro supplementation of IGF-I to
cultured mandibular condyle explants induced an increase
in the cartilaginous layer width in mice. Suzuki et al. [33]
also reported that local administration of IGF-I to articular
capsules of the mandibular condyle increased the amount
of endochondral ossiﬁcation in adult rats. In addition,
immunohistological examination of rat mandibular condyle
shows that IGF-I receptors exist mainly in the condylar
cartilage [34]. It therefore seems indisputable that IGF-
I stimulates endochondral ossiﬁcation in the mandibular
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Figure 7: (a, b) Coronal sections of the cartilaginous layer in
the mandibular condyle in the IGF-I group (a) and the control
group (b) at 14 weeks of age (hematoxylin-eosin staining, 200x
magniﬁcation, bars = 30μm). (c) Width of the cartilaginous layer.
Datarepresentthemean ±SDofsixrats(∗P<0.05versuscontrol);
adapted from a previous report [10].8 International Journal of Endocrinology
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Figure 8: (a, b) Coronal sections of bone matrix in the mandibular condyle in the IGF-I group (a) and the control group (b) at 14 weeks of
age (hematoxylin-eosin staining, 100x magniﬁcation, bars = 100μm). (c–e) Bone matrix ratio (c), number of osteoblasts (d), and number
of osteoclasts (e). Data represent the mean ± SD of six rats (∗P<0.05 versus control), adapted from a previous report [10].
condyles of the rat models. Furthermore, Dellatte et al.
[35] reported that cartilaginous growth in the mandibular
condyle appears to be more sensitive to IGF-I than that
in the femoral head, presumably due to their diﬀerent
cartilage origins (primary and secondary cartilage). Speciﬁc
sensitivity to IGF-I in the mandibular condyle may explain
the speciﬁc mandibular protrusion seen in acromegalic
patients.
To further clarify the bone formation changes that occur
in the mandibular condyle, we also investigated the bone
matrix ratio (the ratio of bone matrix area in the bone
tissue area) and the numbers of osteoblasts and osteoclasts
[10]. The bone matrix ratio was measured on specimens
stained with hematoxylin-eosin (Figures 8(a) and 8(b)).
Osteoblasts and osteoclasts were identiﬁed by osteocalcin
immunoreactivity and by detection of tartrate-resistant acid
phosphatase (TRAP), respectively, with Carazzi’s hema-
toxylin for counterstaining [10] .T h eb o n em a t r i xr a t i o
and number of osteoblasts in the mandibular condyle were
signiﬁcantly greater in rat model compared to control ratsInternational Journal of Endocrinology 9
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Figure 9: Changes in orofacial structures during and after IGF-I administration.
(Figures 8(a)–8(e))[ 10]. This indicates that administration
of IGF-I promotes proliferation of osteoblasts, thereby ac-
celerating bone formation in that part of the mandibular
condyle. In agreement with our results, Mueller et al. [36]
and Wakisaka et al. [37] reported that administration of
IGF-I increases the number of osteoblasts, the trabecular
bone mass, and the bone formation rate. It is now clear that
IGF-I stimulates osteoblasts and promotes bone formation.
There are, however, discrepancies in researchers’ reports
on osteoclasts and IGF-I administration. One publication
reported that IGF-I induces a decrease in the number of
osteoclasts in rat femur and tibia [38], a second reported
an increase in mouse calvarial bone [39], and a third
reported no change in rat femur [37]. Our ﬁndings showed
no signiﬁcant intergroup diﬀerences in the number of
osteoclasts, indicating that IGF-I stimulates osteoclasts less
than it does osteoblasts (Figures 8(d) and 8(e))[ 10].
4. Changes after Cessation of
IGF-IAdministration
4.1. IGF-I Serum Level and Body Weight. After IGF-I admin-
istration was stopped, human IGF-I levels immediately
d e c r e a s e dt oz e r o ,a n dr a tI G F - Il e v e l si m m e d i a t e l yr e t u r n e d
to levels seen in the control group, so that total serum IGF-
I levels were similar in the two groups (Figures 1(a) and
1(b))[7].Thismaybeconsideredconsistentwithourclinical
ﬁnding that the serum IGF-I level normalizes after successful
transsphenoidal surgery in patients with a GH-oma [40].
In two other animal models of acromegaly or acromegaly-
like disease (osteocalcin-IGF-I transgenic mice [41]a n dG H
transgenic mice [42]), investigators were unable to assess
morphological changes after IGF-I normalization because
serum levels of IGF-I in these animal models never returned
to normal. Thus, our rat model appears to oﬀer the advan-
tage of allowing us to assess how changes occur both during
the IGF-I administration itself and after normalization of
the circulating IGF-I level (incidental to discontinuation of
the administration). Body weight fell somewhat immediately
after administration ended and ﬁnally settled at the same
level as the control group (Figure 1(c))[ 7]. These data agree
well with a clinical report [43] showing that the body weight
ofpatientswithaGH-omadecreasesrapidlyfor2weeksafter
successful treatment (in line with rapid decreases in total
body water and body cell mass).
4.2. Tongue. No intergroup diﬀerences in tongue weight
were detected between the IGF-I and control groups after
IGF-I administration ended (Figure 2(b))[ 8]. Similarly,
neither muscle bundle width, ratio of the muscle parts,
nor thickness of the epithelium showed any signiﬁcant
diﬀerences between the IGF-I and control groups after
administration ended (Figures 3(c)–3(e))[ 8]. Thus, changes
in the tongue after overexpression of IGF-I were reversible,
suggesting that enlargement of the tongue in patients
with acromegaly should improve after normalization of
the circulating IGF-I level. Several clinical reports have
described changes in skeletal muscle after successful treat-
ment (surgery) in patients with acromegaly. Decreases in
skeletal muscle volume (observed by multiscan computed
tomography [44]) and skeletal muscle potassium content
(due to decreased stimulation of the Na+-K+ pump [19])
agree well with our ﬁndings. The decrease in the space
between muscle bundles in our rat model may be related
to decreased stimulation of the Na+-K+ pump caused by
normalization of circulating IGF-I levels.
4.3. Jaw Bones. Disharmonious jaw growth, due to excessive
mandibular alveolar bone enlargement and elongation of
condylar length, persisted after normalization of the circu-
lating IGF-I level (Figures 4(c) and 6(b))[ 7, 10]. Similarly,
deformation of mandibular dental arch, caused by lateral
expansion did not return to normal (Figures 5(a)–5(c))
[9]. On the other hand, histopathological changes in the
mandibular condyle (increases in cartilaginous layer width,10 International Journal of Endocrinology
bonematrixratio,andnumberofosteoblasts)werereversible
(Figures 7(c) and 8(c)–8(e))[ 10]. These results suggest that
the hypertrophic external form, modeled by endochondral
ossiﬁcation in the rat condyle, is stable.
5. Conclusion
Figure 9 summarizes our studies on morphological and
histopathological changes in orofacial structures of experi-
mentally developed acromegaly-like rats. Exogenous admin-
istration of IGF-I evoked acromegaly-like speciﬁc enlarge-
ment of the tongue and mandible in rat. After normalization
of the circulating IGF-I level, enlargement of the tongue
and histopathological changes in the tongue and mandibular
condyle also returned to normal, while skeletal morphologi-
cal changes in the mandible remained. Taken together, these
results suggest that the most suitable time to begin occlusal
treatment in acromegalic patients is after improvement of
tongue enlargement, because these treatments must be used
as part of a comprehensive strategy to achieve functional
harmony with the tongue. It is also clear that informed
consent should be sought for additional surgical orthodontic
treatment, because the enlarged mandibular bone may not
return to a normal size on its own accord.
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